Showing 1151-1160 of 1211 results for "".
- ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-receives-fast-track-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2479540/ProQR Therapeutics announced that it received fast track designation from the FDA for QR-1123, a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H mutation
- New Accessible Products Hotline to Offer Advice on Products for Blind or Visually Impairedhttps://modernod.com/news/new-accessible-products-hotline-to-offer-advice-on-products-for-blind-or-visually-impaired/2476823/Envision has launched a first-of-its-kind Accessible Products Hotline that aims to help consumers with vision loss find products that fit their unique accessibility needs. Funded by a grant from the Consumer Technology Association (CTA) Foundation, the hotline will be operated by the William L. H
- Iveric bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapyhttps://modernod.com/news/iveric-bio-announces-successful-advancement-of-lca10-minigene-program-and-expansion-of-orphan-gene-therapy/2476762/Iveric bio announced that the company has exercised its option and entered into an exclusive global license agreement with the University of Massachusetts Medical School for rights to develop and commercialize mutation independent novel adeno-associated virus (AAV) gene therapy product candidates
- FDA Does Not Approve Bausch Health, Eton’s Pharma’s EM-100 for Allergic Conjunctivitishttps://modernod.com/news/fda-does-not-approve-bausch-health-etons-pharmas-em-100-for-allergic-conjunctivitis/2476731/Eton Pharmaceuticals on Friday said that partner Bausch Health Companies has received a complete response letter from the FDA for its filing seeking approval of the investigational therapy EM-100 to treat ocular itching associated with allergic conjunctivitis. “We
- New CPT Code for Automated Point-of-Care Retinal Imaginghttps://modernod.com/news/new-cpt-code-for-automated-point-of-care-retinal-imaging/2476690/Artificial intelligence diagnostics company IDx announced that the American Medical Association (AMA) has accepted a new category 1 CPT code for automated point-of-care retinal imaging. This new code, submitted by the American Academy of Ophthalmology (AAO) with the support of IDx, facilitates co
- Eyepromise Introduces Screen Shield Pro All-Natural Eye Vitamin for Screen Time Protection for Adultshttps://modernod.com/news/eyepromise-introduces-screen-shield-pro-all-natural-eye-vitamin-for-screen-time-protection-for-adults/2476661/EyePromise announced the introduction of Screen Shield Pro to its premium eye vitamin line. EyePromise’s Screen Shield Pro is designed to protect and relieve the associated symptoms of digital eye strain of adults (ages 18 and up) who spend 8+ hours staring at digital screens while working, gami
- A Single Course of Provention’s PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least 2 Yearshttps://modernod.com/news/a-single-course-of-proventions-prv-031-teplizumab-delays-type-1-diabetes-onset-in-high-risk-individuals-by-at-least-2-years/2476644/Provention Bio announced that results from the National Institutes of Health (NIH)-sponsored “At-Risk” Study were published on-line in The New England Journal of Medicine and presented at the Scientific Sessions of the 79th Annual American Diabetes Association (ADA) meeting.
- Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Millionhttps://modernod.com/news/biogen-completes-acquisition-of-nightstar-therapeutics-for-approximately-800-million/2476641/Biogen announced that it has completed its acquisition of gene therapy company Nightstar Therapeutics, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical ass
- PECAA Annual Meeting Draws Record Attendancehttps://modernod.com/news/pecaa-annual-meeting-draws-record-attendence/2476621/PECAA (Professional Eye Care Associates of America) hosted its sold-out annual meeting May 16-18 at the JW Marriott Austin. The member-only event drew a record 900+ individuals from the PECAA community for a mix of bu
- The Maze of Vision Loss and Depression in Older Adultshttps://modernod.com/news/the-maze-of-vision-loss-and-depression-in-older-adults/2476619/“The association between vision loss and depression is a complex conundrum,” Alan R. Morse, JD, PhD, President and CEO of Lighthouse Guild, said in a commentary on the challenges of vision loss and depression in older adults, published today in JAMA O